Why Kellanova Stock Is Trading Higher On Monday

Zinger Key Points
  • Mars is considering acquiring Kellanova.
  • The acquisition of Kellanova would be the biggest ever for Mars.

Kellanova K shares are moving higher on Monday following a report suggesting that Mars is considering purchasing the company.

The Details: Mars, which owns brands such as M&Ms and Snickers, is considering acquiring Kellanova, a snack maker with a market value of approximately $27 billion.

There is no guarantee that Mars will go through with the purchase of Kellanova. However, the acquisition of Kellanova would be the biggest acquisition Mars has ever undertaken, according to Reuters.

Reuters stated that Kellanova declined to comment on the matter and Mars did not immediately respond.

How To Buy Kellanova Stock

By now you're likely curious about how to participate in the market for Kellanova K – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

In the the case of Kellanova K, which is trading at $71.87 as of publishing time, $100 would buy you 1.39 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

Related Link: FDA Panel Backs Zevra’s Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases

K Price Action: K shares are up 14.3% at $72 at the time of writing, according to data from Benzinga Pro.

Image: Courtesy Of Mars.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!